Digoxin

Generic Name
Digoxin
Brand Names
Digox, Lanoxin
Drug Type
Small Molecule
Chemical Formula
C41H64O14
CAS Number
20830-75-5
Unique Ingredient Identifier
73K4184T59
Background

Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
...

Indication

Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.
...

Associated Conditions
Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure
Associated Therapies
-
Clinical Trials
Related News

TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin

First Posted Date
2011-02-02
Last Posted Date
2012-11-30
Lead Sponsor
Tibotec Pharmaceuticals, Ireland
Target Recruit Count
33
Registration Number
NCT01288742

A Study of LY2216684 and Digoxin in Healthy Subjects

Phase 1
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: LY2216684
Drug: Digoxin
First Posted Date
2010-12-24
Last Posted Date
2018-10-22
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
30
Registration Number
NCT01266590
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States

Digoxin for Recurrent Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Drug: Digoxin
First Posted Date
2010-07-14
Last Posted Date
2016-11-29
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
16
Registration Number
NCT01162135
Locations
🇺🇸

Thomas Jefferson University, Philadelphia, Pennsylvania, United States

to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Flibanserin plus Digoxin
Drug: Digoxin
First Posted Date
2010-06-02
Last Posted Date
2011-04-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT01134965
Locations
🇩🇪

511.158.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients

First Posted Date
2010-04-14
Last Posted Date
2011-01-05
Lead Sponsor
AstraZeneca
Target Recruit Count
20
Registration Number
NCT01103622
Locations
🇺🇸

Research Site, Chula Vista, California, United States

Effect Of Maraviroc On The Pharmacokinetics Of Digoxin

Phase 1
Completed
Conditions
Healthy
HIV Infections
Interventions
Drug: Digoxin
Drug: Maraviroc
First Posted Date
2010-01-26
Last Posted Date
2011-04-07
Lead Sponsor
ViiV Healthcare
Target Recruit Count
12
Registration Number
NCT01056874
Locations
🇸🇬

Pfizer Investigational Site, Singapore, Singapore

Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care

First Posted Date
2009-11-01
Last Posted Date
2014-05-22
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
131
Registration Number
NCT01005602
Locations
🇺🇸

University of Illinois at Chicago, Chicago, Illinois, United States

Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

First Posted Date
2009-05-19
Last Posted Date
2016-10-17
Lead Sponsor
AstraZeneca
Target Recruit Count
30
Registration Number
NCT00904176
Locations
🇺🇸

Pra International, Lenexa, Kansas, United States

Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Digoxin
Drug: Neratinib
First Posted Date
2009-03-12
Last Posted Date
2012-05-14
Lead Sponsor
Puma Biotechnology, Inc.
Target Recruit Count
27
Registration Number
NCT00860223

Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects

First Posted Date
2009-01-29
Last Posted Date
2009-06-12
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT00831506
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy